Inhibrx

United States
San Diego, California, United States, 92037

Company profile

Inhibrx company profile

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases, and infectious diseases. Inhibrx has collaborations with Celgene and Bluebird Bio and has received awards from several granting agencies, including NIH, NIAID, and CARB-X.

Business identity

Phone number
(858) 795-4220
Operating status
Closed
Company type
For Profit
Employee range
101-250 employees
Revenue range
$10M-$100M
Founded
2010-01-01, Year

Headquarters

Postal code
92037
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
6
Total equity funding
$203.6M
Last funding
Post IPO Debt / $150M / 2025-01-13
Last equity funding
Post IPO Equity / $200M
Investors
10
Lead investors
4
Founders
3
Articles
107
Closed on
2024-05-30
Exited on
2020-08-18

Founders and investors

Founders

Brendan EckelmanMark LappeQuinn Deveraux

Lead investors

CARB-XOxford Finance LLCRA Capital ManagementViking Global Investors

Investors

CARB-XLilly Asia VenturesPerceptive AdvisorsRA Capital ManagementTCG Crossover